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Abstract
Myelin-associated glycoprotein (MAG) is an inhibitor of axon growth. MAG 
levels increase after stroke. GSK249320 is a monoclonal antibody that neutralizes 
MAG-mediated inhibition and so may promote axon outgrowth and improve 
post-stroke outcomes. The current study tested the hypothesis that GSK249320 
initiated 24 hours or 7 days after experimental stroke improves behavioural 
outcomes. Rats with right middle cerebral artery occlusion for 90 minutes 
were randomized to receive 6 weeks of intravenous (a) GSK249320 starting 24 
hours post-stroke, (b) GSK249320 starting 7 days post-stroke, or (c)  vehicle. 
Behavioral testing was performed over 7 weeks. Serial MRI demonstrated no 
differences in infarct volume across groups. Animals treated with GSK249320 
24 hours post-stroke showed larger increases in Neuroscore (time X group, 
p = 0.0008) and staircase test (main effect of group, p = 0.0214) as compared to 
controls, but animals treated 7 days post-stroke showed no significant behavioral 
benefit. No significant results were found for the sticky tape or cylinder tests. A 
separate set of animals with experimental stroke received a single intravenous 
dose of GSK249320 or vehicle at 1 hour, 24 hours, 48 hours or 1 week post-
stroke, and immunohistochemistry methods were used to measure GSK249320 
distribution; GSK249320 was found in the ipsilesional hemisphere only, the 
extent of which increased with later times of injection. These data suggest that 
intravenous GSK249320 penetrates the lesion site and is associated with a small 
effect on functional outcomes when initiated 24 hours post-stroke and so support 
the translational potential of this monoclonal antibody as a restorative therapy for 
patients with stroke.
Keywords
Stroke, Axon, Plasticity, Recovery, Treatment, Translation 
Abbreviations
MAG: Myelin-associated glycoprotein; NgR: Nogo-66 neuronal receptor; 
MCAO: Middle cerebral artery occlusion
Introduction
There are no approved therapies for improving deficits post-stroke that are 
initiated beyond the first few hours.  Furthermore, in most studies where patients 
do receive an approved acute stroke therapy, most patients are left with significant 
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followed by 4% paraformaldehyde. All models used in these 
studies conformed to UK standards of animal care as laid 
down by the Home Office.
Treatment
Rats were assigned to treatment groups using randomized 
block design; the blocks were stratified according to weight 
and animals within each block randomly assigned to one of 
three treatment groups.  Animals then received IV injections 
through a tail vein of GSK249320 at 10 mg/kg starting 
24 hours post-stroke (“MAG 24 hour”) and continuing weekly 
for 6 more doses (n = 14), GSK249320 at 10 mg/kg starting 
seven days post-stroke (“MAG 7d”) and continuing weekly 
for 5 more doses (n = 19; note that these animals also received 
an IV injection of vehicle 24 hours after MCAO), or vehicle 
starting 24 hours post-stroke (“VEH”) and continuing weekly 
for 6 more doses (n = 17). Animals were weighed at baseline 
then weekly.
The monoclonal antibody (GSK249320, molecular 
weight of 151.3 kDa) was received from GSK and diluted to 
10 mg/ml before use. Solutions were stored at 4 °C. 
GSK249320 is expressed as a soluble glycoprotein secreted 
from a recombinant Chinese Hamster Ovary-DG44 cell line.
Behavioral assessments  
A multi-part motor scale and four functional tests were 
assessed in the left (contralesional) paw. 
The Neuroscore
This 9 part neurological assessment was assessed using 
modifications of Hunter et al. [16] and Modo et al. [17]. This 
battery assesses spontaneous motility, grooming, righting 
reflex, ability to grip a horizontal bar, visual paw placement, 
spontaneous and induced (via tail lift) circling, forelimb 
flexion, and contralateral reflex (lateral push). Maximum score 
is 18. Scoring was performed once before surgery, daily for the 
first seven days after MCAO, and then once/week thereafter.
The staircase test
This test was performed as described by Virley et al. [15], 
using coco-pop pellets (Tesco) as food bait. This was performed 
2, 4 and 6 weeks after MCAO. Before each test session the 
rats were placed on a mild food restriction diet comprising of 
15 g food pellets per rat (previously determined to be needed 
to maintain rats at 80-85% of free feeding weight). Prior to 
this, animals were trained each weekday for 3-4 weeks before 
surgery until they satisfied inclusion criteria of retrieval of 
at least 2 coco-pops, and displacement of less than 7 coco-
pops, per side per day for 3 consecutive days. Performance was 
scored as the number of coco-pops recovered and/or displaced 
from each side. Each data point represents the mean of two 
trials per day over three days of testing per time-point. The 
last three training days pre-surgery, after the animal satisfied 
inclusion criterion, were used as the baseline score. 
The sticky tape test of sensorimotor neglect 
For the sticky tape test [18] a 1 cm-wide strip of sticky 
tape (Micropore, 3M) was firmly wrapped around each 
deficits despite overall efficacy.  Therapies based on brain repair 
have the potential to improve outcomes with a relatively wide 
time window.
One class of repair-based therapy revolves around 
promoting axon outgrowth to augment neuroplasticity. 
Such therapies target myelin-associated axon outgrowth 
inhibition molecules, which promote a non-permissive growth 
environment after stroke and so reduce neurite outgrowth [1-3]. 
Three major inhibitors of axon growth have been identified 
in myelin: oligodendrocyte-myelin glycoprotein, Nogo-A, 
and myelin-associated glycoprotein (MAG).  Each is located 
in the periaxonal surface of the myelin membrane, binds to 
the Nogo-66 neuronal receptor (NgR), and activates the 
small GTPase Rho-A [4, 5]. Several studies, using divergent 
approaches, indicate that blockade of MAG promotes axonal 
growth and can improve recovery [5-11].
After stroke, MAG expression increases [12], further 
highlighting the potential to target post-stroke molecular 
events in order to promote neuroplasticity. GSK249320 is an 
IgG1-type humanized monoclonal antibody that neutralizes 
MAG-mediated inhibition [10]. A theoretical concern for an 
anti-MAG antibody is the potential to cause a demyelinating 
peripheral neuropathy, however, the Fc region of GSK249320 
is disabled, preventing the complement fixation that is central 
to the pathophysiology of anti-MAG antibody neuropathy 
[13], and furthermore the anti-MAG antibodies associated 
with neuropathy are IgM not IgG [14].
The current study tested the hypothesis that GSK249320, 
an anti-MAG monoclonal antibody, when initiated 24 hours 
or later after induction of an experimental stroke in rodents, 
would be an effective restorative therapy, improving long-
term behavioural outcomes without modifying infarct volume. 
Regarding choice of behavioural outcomes, the current focus 
is on the motor system, which is commonly affected in human 
subjects with stroke and which contributes substantially to 
disability. A secondary aim was to examine penetration of 
GSK249320 into the brain in rodents with an experimental 
stroke.
Materials and Methods
Experimental infarct  
Surgery was performed on 66 male Sprague Dawley 
rats (Charles River, UK; weight 361 ±  21 g, mean ±  sd) 
under isoflurane anesthesia (in O2: medical air 20:80) by 
occluding the right middle cerebral artery (MCA) for 90 
minutes with intraluminal thread (silicone rubber coated 5.0 
monofilaments, tip diameter 0.33 ±  0.02 mm, from Doccol 
Corporation, USA) as previously described [15]. A total of 16 
rats were excluded from the study because of sub-arachnoid 
hemorrhage (confirmed by MRI at 24 hour post-surgery, 
n = 8), because they died overnight (n = 3), or because were 
euthanized the day after surgery (n = 3) or at a later date 
(n = 2) due to excessively severe symptoms as required by the 
Home Office Project Licence. At the end of the experiment, 
on day 63 after middle cerebral artery occlusion (MCAO), 
animals were killed by transcardial perfusion with 0.9% saline, 
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forepaw.  The latency to remove the tape was recorded in two 
trials per test point, each trial lasting up to three minutes. This 
test was conducted at 1, 3, 5 and 7 weeks after MCAO. Each 
data point represents a mean of two trials. Prior to MCAO 
surgery, animals were trained in four such sessions; the fifth 
session (1-3 days before MCAO) was used as the baseline 
measure. 
The cylinder test of forelimb-use asymmetry
  The cylinder test [18] was conducted by placing rats inside 
a glass beaker (28.5 cm height and 13 cm base diameter) for 
up to 3 minutes, and the number of contacts between the glass 
wall and each forepaw was counted. This test was performed 
at 1, 3, 5 and 7 weeks after MCAO. Each test point comprised 
two such trials and each data point represents a mean of the 
two trials. 
The sticky tape test of sensorimotor neglect [18] and the 
cylinder test of forelimb-use asymmetry [18] were conducted 
at 1, 3, 5 and 7 weeks after MCAO. 
Brain imaging
  An MRI of the brain including T2-weighted anatomical 
images (TR = 4000 ms, TE = 60 ms, 45 x 0.6 mm thick slices 
with 0.31 x 0.31 mm in-plane resolution) was acquired at 24 
hour post-stroke (prior to treatment in any group), and at the 
end of the experiment 63 days post-stroke. Lesion topography 
was determined from the first MRI (24 hour post-stroke), 
with infarcts classified as either (a) full MCA territory, i.e., 
involving cortical and subcortical regions, or (b) subcortical 
only, generally involving the striatum. Infarct volume was 
measured using DispImage software (D. Plummer, UCL) 
by contouring the lesion outline that remained after images 
were thresholded above 2SD of the MR signal intensity in 
the unaffected contralateral hemisphere. Brain volumes were 
obtained by automatic contouring.
GSK249320 entry into the brain after stroke
A separate set of rats underwent MCAO as above. 
Animals were injected IV with either vehicle or a single dose 
of GSK249320 at a concentration of 10 mg/kg, at either 1 
hour, 24 hours, 48 hours or 1 week following MCAO (n = 6 in 
each group). In order to determine antibody distribution in the 
brain, animals were killed by transcardiac perfusion with ice-
cold saline, followed by 4% paraformaledehyde.  Brains were 
stored in ice-cold 4% paraformaledehyde for 48 hours, then 
processed for paraffin embedding and subsequent histological 
analysis. Lesioned areas were delineated as areas of tissue with 
reduced haematoxylin and eosin.
In order to assess GSK249320 in these brains, paraffin 
embedded brain sections were cut at 4 μm, de-waxed, and 
hydrated into distilled water. An antigen retrieval method 
using Proteinase K (Dako:S3020) was applied to the sections 
for 5 minutes, after which slides were washed well in distilled 
water. Using a DAKO autostainer machine, Donkey anti-
Human IgG (1:500, Jackson: 709-035-149) was applied 
to sections for 30 minutes, followed by an appropriate 
biotinylated anti-donkey IgG (1:200, Abcam: AB6764) for 30 
minutes. Visualisation was accomplished using Vector ABC 
and DAB systems. Sections were then dehydrated, cleared and 
mounted. 
Statistical analysis
All data analysis used repeated measures or n-way 
ANOVA, with Fisher LSD post-hoc tests used to determine 
pairwise differences between experimental groups. Where 
terms for time or lesion topography were included in the 
model, comparisons between experimental groups were 
made at the highest level interaction term. All analyses were 
performed, and graphs produced, in Statistica 8.0 (StatSoft). 
Significance was defined at p < 0.05. Where necessary, data 
were transformed prior to analysis in order to satisfy the 




The compound did not affect animals’ weight, and 
no significant difference in weight between groups was 
found, including when lesion topography was taken into 
consideration.
Imaging
 Infarct volumes decreased over time (from 256.9 ± 16 mm3 
at 24 hour post-MCAO to 119.5 ± 6 mm3 at 46 days post-
MCAO, mean ± SEM).  There were no significant differences 
between the three treatment groups at either time point or 
over time. Also, there were no differences in brain volumes 
over time or between experimental groups. Lesion topography 
classification as determined from the 24 hour post-MCAO 
MRI found that the MAG 24 hour group had 7 full (cortical 
and subcortical) and 7 subcortical only strokes, the MAG 7d 
group had 11 full and 8 subcortical strokes, and the VEH 
group had 8 full and 9 subcortical strokes.
Neuroscore 
 There was a significant interaction term in the repeated 
measures ANOVA between time and treatment group 
(p = 0.0008) that was not dependent on lesion topography 
(Figure 1). Post-hoc testing revealed significant (p < 0.05) 
increases in the Neuroscore for MAG 24 hour vs VEH, on 
weeks 2 and 4 post-MCAO.
Staircase test 
Repeated measures ANOVA found the main effect of 
treatment group to be significant, in the group of animals 
with subcortical lesions only (p = 0.0214, Figure 2). Post-hoc 
testing revealed a significant increase in the number of pellets 
retrieved for MAG 24 hour animals as compared to VEH on 
weeks 2, 4, and 6 in this group (p = 0.0261, 0.0021, and 0.0007, 
respectively).
Sticky tape test 
There were no significant differences between treatments 
groups over time (Figure 3).
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Cylinder test
There were again no significant differences between 
treatments groups over time (Figure 4).
GSK249320 entry into the brain after stroke
 At all four post-MCAO time points examined, 
administration of GSK249320, followed by sacrifice and 
perfusion 6 hours later, revealed staining for GSK249320 
in the ipsilesional, but not contralesional, hemisphere, and 
no staining was seen in either brain hemisphere following 
vehicle administration (Figure 5). This ipsilesional hemisphere 
staining 6 hours following IV GSK249320 administration was 
light when GSK249320 was introduced 1 hour post-MCAO, 
moderate when GSK249320 was introduced at 24 hours 
post-MCAO, strong when GSK249320 was introduced at 
48 hours post-MCAO, and strongest when GSK249320 was 
introduced at 7 days post-MCAO. 
 
Discussion
Restorative therapies aim to promote repair after stroke 
and so complement neuroprotective and reperfusion therapies 
given in the initial hours after stroke, which aim to reduce 
injury.  Consistent with this, GSK249320, a restorative 
Figure 1: Change in Neuroscore over time according to stroke subtype.  Mean 
values are plotted with 95% confidence intervals. [A] Data from animals with 
a full MCA territory infarct. [B] Data from animals with a subcortical infarct.
Figure 2: Change in staircase test over time according to stroke subtype (square 
root transform).  Mean values are plotted with 95% confidence intervals. [A] 
Data from animals with a full MCA territory infarct. [B] Data from animals 
with a subcortical infarct. *specific timepoints where a significant increase was 
seen in the number of pellets retrieved for MAG 24h animals (subcortical 
infarct group) as compared to VEH in post hoc testing.
Figure 3: Change in sticky tape test over time according to stroke subtype. 
Mean values are plotted with 95% confidence intervals. [A] Data from animals 
with a full MCA territory infarct. [B] Data from animals with a subcortical 
infarct.
Figure 4: Change in cylinder test over time according to stroke subtype.  Mean 
values are plotted with 95% confidence intervals. [A] Data from animals with 
a full MCA territory infarct. [B] Data from animals with a subcortical infarct.
Figure 5: Staining for GSK249320 in the ipsilesional hemisphere.
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therapy that aims to improve outcomes by blockage of MAG, 
penetrated lesion sites and improved behavioral outcomes 
without having an effect on infarct volume.  Effects were most 
pronounced in animals receiving GSK249320 beginning 24 
hours post-MCAO. Significant effects were found for two 
of the four measures, Neuroscore and staircase test, although 
this must be considered a small effect given that findings were 
significant only at some of the time points, and for the staircase 
test only in animals with a subcortical infarct. Data confirm 
that GSK249320 is able to enter the brain at this time post-
injury.  Together these results support the potential utility of 
GSK249320 as a restorative therapy in the treatment of stroke.
These studies examined the ability of GSK249320, a 
monoclonal antibody against MAG, to improve functional 
outcomes in a rat model of ischemic stroke. MAG expression 
inhibits neurite outgrowth and therefore limits CNS 
regeneration.  MAG expression increases after stroke [12], 
further increasing the potential importance of this molecule 
as a therapeutic target. Prior studies support the hypothesis 
that blockade of MAG promotes axonal growth:  introduction 
of a dominant-negative form of NgR in rodents substantially 
reduces the inhibitory effects of MAG, MAG inhibition of 
developing cerebellar or dorsal root ganglia neurite outgrowth is 
reversed in vitro by an anti-MAG antibody, immunodepletion 
of MAG from bovine CNS myelin substantially diminishes its 
neurite outgrowth inhibitory activity, and inactivation of the 
small guanosine triphosphatase (GTPase) Rho-A as well as its 
downstream effector Rho-associated serine-threonine kinase 
reduces MAG-mediated neurite outgrowth inhibition [5, 6, 
9]. GSK249320, as a therapy designed to neutralize MAG, 
aimed to build on these observations and was hypothesized 
to increase clinically favorable neural plasticity and promote 
improved outcomes after brain injury such as stroke. 
The current results support this hypothesis. The Neuroscore 
showed benefit from GSK249320 (Figure 1) that appeared to 
begin emerging within days of first administration, in both 
cortical strokes and subcortical strokes, and this was most 
significant in the group receiving the antibody 24 hours post-
stroke. This scale assesses a range of motor-related behaviors 
such as motility, righting, paw placement, and circling, and 
so provides a rationale for translational studies that focus on 
motor-related behaviors. The staircase test (Figure 2) found 
benefit from GSK249320, but only in animals with subcortical 
stroke, and this was significant in the group receiving the 
antibody 24 hours post-stroke. One reason for a greater effect 
in animals with a subcortical infarct may be a floor effect of the 
staircase test in animals with severe brain injury. This might 
also suggest that any translational studies of GSK249320 could 
have greater effect in patients with strictly subcortical stroke, 
which constitute 50 [19] to 66% [20] of all ischemic strokes, 
although this consideration must be viewed with caution given 
the limited sample sizes in the current study. GSK249320 was 
not superior to control on the simple tests of asymmetry and 
basic limb use, possibly suggesting broad effects on complex 
motor networks. Histological studies found that GSK249320 
entered the ipsilesional hemisphere as early as 1 hour after 
MCAO (Figure 5), with increasing antibody ingress over time. 
Together these results suggest that blockade of MAG is an 
effective strategy to access brain tissue surviving an infarct, 
where the antibody has the effect of improving behavioral 
outcomes, that this effect is superior with earlier exposure, 
and that there may be some advantage when the infarct is 
subcortical. The finding that some behavioral measures were 
positive and others were not, that any significant effects were 
present only on some of the days examined, and that results 
were significant for only subcortical stroke for one of the 
measures indicate that behavioral effects while significant 
were small.
GSK249320 entered the ipsilesional hemisphere at all 
time points examined, being greater when introduced 7 days 
post-stroke as compared to 24 hours post-stroke. Antibodies 
normally have low efficiency to cross the blood-brain barrier 
(BBB) [21], and so the finding that GSK249320 accumulated 
preferentially within the ipsilesional hemisphere over time 
supports the idea that it may have entered the brain more 
efficiently due to defects in BBB integrity created by the stroke. 
Although ipsilesional staining was maximal when GSK249320 
was introduced 7 days after stroke, significant behavioral gains 
were only seen when GSK249320 was initiated 24 hours post-
stroke. Antibody entry alone may therefore be insufficient 
to promote neural repair and improve behavioral outcomes. 
A number of genetic, physiological, and biochemical events 
are in flux between days 1 and 7 post-stroke [12, 22-24]. 
The exact factors that might have mediated the differences 
in GSK249320 effects according to time of administration 
cannot be determined in the current study, however, it is 
noted that current findings are consistent with prior studies 
that administered growth factors to rats at varying times 
post-stroke.  For example, Ren et al. [25] found that initiating 
osteogenic protein-1 to rats with experimental infarct 1 or 3 
days, but not 7 days, post-stroke improved motor behavioral 
outcomes, and Kolb et al. [26] found that sequential growth 
factors (epidermal growth factor followed by erythropoietin) 
initiated 0 or 3 days post-stroke showed greater behavioral 
gains compared to when therapy was initiated 7 days post-
stroke. These results emphasize the importance of time post-
stroke in the design of restorative therapy protocols for this 
disease setting.
Prior studies in rodents found that after CNS injury, 
an antibody against MAG can neutralize MAG-mediated 
inhibition, promote neuritic outgrowth, and improve 
behavioral recovery [10, 11]. The current study builds on these 
findings, providing evidence that GSK249320, an anti-MAG 
monoclonal antibody, initiated IV 24 hours after stroke onset 
enters the ipsilesional hemisphere and is associated with a small 
effect on functional outcomes. This study was conducted in a 
manner concordant with STAIR criteria [27] and so supports 
the translational potential of this monoclonal antibody as a 
restorative therapy in patients with stroke.
Conclusion
Intravenous GSK249320 penetrates the lesion site and is 
associated with a small effect on functional outcomes when 
initiated 24 hours post-stroke
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